MX2021003845A - Composiciones para reducir el acido urico serico. - Google Patents

Composiciones para reducir el acido urico serico.

Info

Publication number
MX2021003845A
MX2021003845A MX2021003845A MX2021003845A MX2021003845A MX 2021003845 A MX2021003845 A MX 2021003845A MX 2021003845 A MX2021003845 A MX 2021003845A MX 2021003845 A MX2021003845 A MX 2021003845A MX 2021003845 A MX2021003845 A MX 2021003845A
Authority
MX
Mexico
Prior art keywords
compositions
uric acid
serum uric
reducing serum
methods
Prior art date
Application number
MX2021003845A
Other languages
English (en)
Inventor
Johan Hoegstedt
James Mackay
Eva Johnsson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2021003845A publication Critical patent/MX2021003845A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente divulgación proporciona composiciones que comprenden verinurad, un inhibidor de la xantina-oxidasa y dapagliflozina útiles para reducir los niveles de ácido úrico sérico, formulaciones que las contienen y métodos para utilizarlas. En algunas realizaciones, los métodos y composiciones descritos en la presente se utilizan en el tratamiento o prevención de afecciones asociadas con la hiperuricemia, tales como la nefropatía crónica, insuficiencia cardiaca y gota.
MX2021003845A 2018-10-01 2018-10-01 Composiciones para reducir el acido urico serico. MX2021003845A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2018/057612 WO2020070539A1 (en) 2018-10-01 2018-10-01 Compositions for reducing serum uric acid

Publications (1)

Publication Number Publication Date
MX2021003845A true MX2021003845A (es) 2021-05-27

Family

ID=63965710

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021003845A MX2021003845A (es) 2018-10-01 2018-10-01 Composiciones para reducir el acido urico serico.

Country Status (13)

Country Link
US (1) US20210338648A1 (es)
EP (1) EP3860601A1 (es)
JP (1) JP2022511380A (es)
KR (1) KR20210069685A (es)
CN (1) CN112789041A (es)
AU (1) AU2018444285A1 (es)
BR (1) BR112021006002A2 (es)
CA (1) CA3113376A1 (es)
EA (1) EA202190841A1 (es)
IL (1) IL281740A (es)
MX (1) MX2021003845A (es)
SG (1) SG11202103078WA (es)
WO (1) WO2020070539A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3181902A1 (en) * 2020-06-10 2021-12-16 Litain YEH Methods for treating or preventing chronic kidney disease
CA3188345A1 (en) * 2020-07-10 2022-01-13 Astrazeneca Ab Combination of zibotentan and dapagliflozin for the treatment of chronic kidney disease
WO2022162021A1 (en) * 2021-01-27 2022-08-04 Astrazeneca Ab Verinurad compositions and methods of use
WO2023149701A1 (ko) * 2022-02-07 2023-08-10 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 심혈관 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
KR20230119303A (ko) * 2022-02-07 2023-08-16 (주)인드림헬스케어 높은 혈중 요산 농도를 갖는 대상체의 만성 신장 질환의 예방 또는 치료를 위한 알로푸리놀, 페북소스타트 또는 이들의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
CN102105153B (zh) * 2008-05-22 2014-03-05 百时美施贵宝公司 Sglt2抑制剂的医药用途和含该抑制剂的组合物
WO2012050589A1 (en) * 2010-10-15 2012-04-19 Ardea Biosciences, Inc. Methods for treating hyperuricemia and related diseases
US20180360761A1 (en) * 2015-12-08 2018-12-20 Ardea Biosciences, Inc. Pharmaceutical composition comprising a potent inhibitor of urat1

Also Published As

Publication number Publication date
EA202190841A1 (ru) 2021-07-15
SG11202103078WA (en) 2021-04-29
BR112021006002A2 (pt) 2021-06-29
AU2018444285A1 (en) 2021-05-20
KR20210069685A (ko) 2021-06-11
JP2022511380A (ja) 2022-01-31
WO2020070539A1 (en) 2020-04-09
IL281740A (en) 2021-05-31
US20210338648A1 (en) 2021-11-04
CA3113376A1 (en) 2020-04-09
EP3860601A1 (en) 2021-08-11
CN112789041A (zh) 2021-05-11

Similar Documents

Publication Publication Date Title
MX2021003845A (es) Composiciones para reducir el acido urico serico.
EA201100441A1 (ru) Соединения для коррекции уровня мочевой кислоты и способы их применения
EP4219716A3 (en) Nucleic acids for inhibiting expression of lpa in a cell
WO2018017368A9 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING A SYMPTOM ASSOCIATED WITH GUT OR HYPERURICEMIA
GEP20135724B (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for treatment or prevention of diabetes
SG156681A1 (en) Use of ranolazine in combination with at least one remodeling agent for reversing left ventricular remodeling in the treatment of heart failure
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
WO2019133770A3 (en) Glycolate oxidase inhibitors for the treatment of disease
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
MX2018002658A (es) Derivados del anillo (hetero) aromatico sustituidos con carboxi, su metodo de preparacion y sus usos.
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
PH12021550801A1 (en) Nucleic acids for inhibiting expression of lpa in a cell
JOP20210193A1 (ar) مثبطات pcsk9 وطرق استخدامها
EP3907283A3 (en) Buffers for stabilization of lentiviral preparations
WO2006057674A3 (en) COMPOSITIONS AND METHODS FOR EX VIVO PRESERVATION OF BLOOD VESSELS FOR VASCULAR GRAFTS USING ANALOGUES OF cAMP AND cGMP
MX2022001004A (es) Inhibidores de enzimas.
MX2021010545A (es) Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de la disfunción crónica del aloinjerto pulmonar.
AU2020258568A8 (en) CD73 inhibitors
MX339829B (es) Metodo para estabilizar daño de articulacion en sujetos utilizando inhibidores de xantina oxidoreductasa.
MX2021010264A (es) Formulaciones estables de proteina.
MX370492B (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3, 2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa.
WO2020247701A3 (en) Inhibitors of sarm1
EA202092748A1 (ru) Модуляторы экспрессии apol1
WO2018209192A8 (en) HUMOCYSTEINE DEPLETION, HUMAN ENZYME MEDIATION, FOR THE TREATMENT OF PATIENTS WITH HYPERHOMOCYSTEINEEMIA AND HOMOCYSTINURY
AU2020378127A8 (en) Compounds as CD73 inhibitors